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Chondroitin sulfate (CS) is a naturally occurring bio-polymer found in areas of high 
cartilage in mammals. In directed applications, such as hydrogels, CS can be used to 
impact keratinocyte growth cycles. In this work, CS based hydrogels were utilized to 
accelerate wound healing and, in conjunction with a graphene sensor, monitor wound 
fluid pH. The hydrogels were cast onto a graphene field effect transistor (GFET) to 
obtain the benefits of the hydrogel wound healing capabilities, while also utilizing the pH 
sensitivity of the graphene. Results showed that the hydrogel caused a fivefold increase in 
cell size over the course of 5 days compared to the control, and accelerated keratinocyte 
proliferation by an average of 81% when compared to a control. The GFET resistance 
changed as a function of pH, however, the resulting pH response was parabolic. Further 
investigation into pH sensitive 2D materials may be necessary in order to optimize and 
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1. Literature Review 
1.1 Introduction 
 Disruptions in the epidermal matrix lead to wounding, where trauma or disease are 
the primary modes. Healing begins shortly after wounding occurs, and is comprised of 
three phases: 1) inflammatory, 2) proliferative, and 3) maturation. Wound type depends on 
wound progression through healing, leading to the development of two main 
classifications, acute and chronic. Acute wounds heal in an orderly and efficient manner, 
characterized by specific biological markers such as metalloproteinase enzymes and tissue 
inhibitor of matrix metalloproteinases. In general, acute wounds last a maximum of 30 
days, with normal healing completed in 5 to 10 days.1-4 Complications with any of the 
wound healing phases leads to chronic wound development. Chronic wounds are 
characterized by a prolonged presence and excess of biological markers, indicating an 
incomplete process where healing now takes months instead of weeks. For Americans this 
represents a significant healthcare impact: exceeding 40 billion dollars and effecting 6.5 
million people, annually.5 This literature review covers biological events that occur in 
wound healing, strategies employed to monitor and accelerate the wound healing process, 
as well as presents evidence for efficacy for current hemostatic products, and determines 
the evidence for translating this technology into the prehospital civilian use. 
Wound care, historically, has been superficial at best; patients were treated with 




disused cloth, introducing pathogenic agents into the wound matrix. Present consumer 
solutions include bandages, formed of polymeric composites and absorbent fibers, and 
topical antibiotic ointments. These bandages serve as a barrier between the superficial 
epidermis and environmental factors. The polymeric composites adhesive property allows 
for the application of mechanical pressure over the wound surface, promoting clotting. 
Absorbent fibrous components allow for wound fluid passage and containment. Topical 
antibiotic ointments are used in concert with bandages; where their efficacy is derived from 
their molecular constituents: neomycin sulfate, polymyxin B sulfate, and bacitracin zinc, 
all antibiotic agents.6-8  
Over time, treatment has progressed to include targeted biological therapies. 
Adhesive bandage packs now include treatments derived from various biomaterials and 
minerals, with biochemically and physiologically beneficial treatment mechanisms.8 Of 
note are: neomycin sulfate, polymyxin B sulfate, bacitracin zinc, chondroitin sulfate, and 
zeolite. 
Chondroitin sulfate is a sulfated glycosaminoglycan (GAG), comprised of an 
alternating chain of sugars (N-acetylgalactosamine and glucuronic acid). It is commonly 
found as a part of a proteoglycan, attached to proteins.9 The alternating chains of sugars 
allow for variable sulfonation, in mutable quantities and position, as evidenced by the 
existence of chondroitin sulfate A, C, D, E, H, and K.10 In nature, it is found   in cartilage, 




aluminosilicates of sodium, potassium, calcium, and barium.12 Zeolite is readily hydrated 
and dehydrated and functions as a cation exchanger and molecular sieve. Commercially, it 
is sold as QuikClot, and facilitates the activation of clotting proteins.13 
Biosensors are devices which utilize analytical methods to detect and quantify 
signals related to biomolecular elements. They use transducers to generate a defined signal 
from a sample.14-15 A typical biosensor system setup is composed of a bio-receptor in 
conjunction with a transducer. The bio-receptor is utilized to recognize biomolecular 
elements, for example: antibodies, enzymes, DNA, RNA, and cells.16 Signal detection by 
the receptor occurs in various quantities and is transduced by: chemical, optical, physical, 
thermal, or electrochemical phenomena into quantitative information for analytical 
processing.17  
Historically, advances in prehospital and operative care were facilitated through 
developments from war and conflict, where the trauma lessons learned are translated to 
civilian medicine.18-19 Since 2001, the beginning of the conflicts in Afghanistan and Iraq, 
advances in trauma care have been made to mitigate morbidity and mortality based on more 
than 52,000 United States (US) combat casualties.20 Technologies that have been translated 
to the civilian sector include: external and internal hemorrhage control, coagulopathy, 
acidosis, and blood component therapy.21-23 
In spite of these translations, hemorrhage is still the leading cause of combat fatality 




injury.21,24-25 As a consequence, major research thrusts into hemorrhage control over the 
last 15 years have focused on wounds that are potentially survivable.21 In civilian trauma 
epidemiological studies conclusions were been made that early trauma deaths (from 
immediately on scene to 24 hours after) due to hemorrhage are deemed survivable, only if 
the necessary personnel and resources are on hand.24 
Research into topical hemostatic agents has grown since 2000, where the majority 
of research concludes their superior utility over plain gauze in controlling severe 
hemorrhage.20 In addition to innovations in research, great strides have been made for 
trauma related training for military personnel (i.e. when to use tourniquets and hemostatic 
dressings) learning to control bleeding and prevent shock and fatality.22,23 Hemostatic 
agents play an integral role in augmenting external hemorrhage control when the location 
of bleeding is in a junctional region such as: the neck, axilla, and groin. 
Due to the strides made in efficacy, hemostatic agents and dressings have been 
adopted into Tactical Combat Casualty Care (TCCC) guidelines since 2003.20,25 In addition 
to hemostatic dressings, pressure dressings, tourniquets, chest seals, and other pressure 
utilizing systems are found in the military individual first aid kit.26 These systems have 
played an integral role in successfully controlling extremity and compressible junctional 
hemorrhage in US and North Atlantic Treaty Organization (NATO) military personnel.27-




regarding how widespread combat casualty lessons learned for hemostatic dressings are 
translated into civilian practice.29  
1.2. Inflammatory Phase 
 Inflammation is a physiological phenomenon where the body’s white blood cells 
provide protection from foreign microbial invasion or trauma.30 There are five cardinal 
signs of inflammation: 1) heat, 2) pain, 3) redness, 4) swelling, and 5) loss of function. The 
inflammatory process occurs immediately after living tissue has been broken.1 
Physiological indicators for wound inflammation are coagulation, hemostasis, chemotaxis, 
and increased vascular permeability. As in-vivo fluid begins to congeal, biochemical 
gradients are created which are utilized by constituent cells to prevent exsanguination. In 
general, the inflammatory phase mainly functions to maintain structural integrity of the 
dermal domain and to provide an initiation matrix for other cells to utilize in the subsequent 




Cellular constituents in the inflammatory phase include: endothelial cells 
and thrombocytes. Together, these cells regulate the fibrinolysis process, which is 
represented in Figure 1.31   
In summary, tissue plasminogen activator (t-PA) and urokinase convert plasminogen to 
active plasmin. This conversion process initiates fibrinolysis (enzymatic breakdown of 
fibrin). Damage caused in the endothelium and surrounding blood vessels releases t-PA to 
mitigate clot formation. Clot break down occurs after several days, indicating break down 
depends on t-PA accumulation. Due to entrapped plasminogen in clots, activation degrades 
the fibrin mesh. Urokinase and t-PA are inhibited by plasminogen activator inhibitor-1/2 
(PAI-1, PAI-2), activation is governed by t-PA and urokinase concentrations. Further, 
plasmin inactivation is mediated by Alpha 2-antiplamin, alpha 2-macroglobulin, and 




thrombin-activated fibrinolysis inhibitor.31 The latter induces conformational changes in 
fibrin to promote t-PA-mediated plasminogen resistance.2 
 Microvascular injury causes an influx of blood into the wound space.3 Contractions 
within the vascular smooth muscle matrix constrict injured blood vessels. This results in 
the stoppage of bleeding; however, efficacy is only defined in blood vessels which are 
located transversely to the constricting muscle. The hypoxic and acidic environment 
created in-vivo allows continuation for several minutes. Consequently, bleeding resumes 
as the wound wall relaxes.32 In order to limit blood loss, clots are formed and platelets 
aggregate, which is mediated by the coagulation cascade.32  
Platelet cytoplasm constituents include: vasoactive amines and α-granules filled 
with growth factor cytokines: platelet derived growth factor (PDGF), transforming growth 
factor (β (TGF-β), epidermal growth factor, and insulin like growth factor. These growth 
factors are concert molecules, promoting completion of the inflammatory cascade.  
Chemo-attractive agents, such as TGF-β, C2a, C5a, and formyl methionyl peptides 
initiate activation of the complementary wound healing cascade. This cascade is 
responsible for infiltration of the wound site by neutrophils. Neutrophils begin the process 
of phagocytosis, acting as a cleaning step for any potentially foreign pathogenic 
constituents. Neutrophil attraction occurs 24-36 hours after tissue damage. Once neutrophil 
infiltration is complete, alterations in regulatory surface adhesion molecules allow for 




As blood continues to spill into the wound site, blood components interact with 
exposed collagen structures. Due to its high amount of dissolved oxygen, the blood exhibits 
highly corrosive properties.31,34 This interaction triggers the release of fibronectin, fibrin, 
vitronectin, and thrombospondin, all clotting factors, as described in Figure 2.34 The overall 
impact of the release of these clotting factors leads to the development of a temporary 
matrix for cell locomotion. Continued blood flow pushes neutrophils toward the wound 
site to initiate phagocytosis. Following wound clean up, neutrophils are eliminated and 
extruded to the wound surface by apoptosis. Macrophages begin further clean-up of cell 
remnants and apoptotic bodies.  
48-72 hours after wounding, macrophages continue phagocytosis. Arrival of 
macrophages is indicative of continual pH fluctuations. Figure 335 represents the entire 
wound healing process with respect to time, major skin healing events, and cell 






Figure 3. The healing time frame expressed in days (D), weeks (W) and years (Y); ii) 





Further, macrophages act as a repository for previously mentioned growth factors 
and mediators.36-38 Lymphocyte arrival is mediated through attraction to interleukin-1 (IL-
1) and immunoglobulin G (IgG) metabolic products. These constituents regulate 
collagenase activity, which governs collagen remodeling, cellular matrix component 
production, and catabolism.39 This process is summarized in Figure 4.40  
1.3. The Proliferative Phase: 
Proliferation is the next step in the wound healing cascade. The proliferation process 
is characterized by re-epithelization, vascular network restoration, and granulation tissue 
formation. Re-epithelization is mediated by a variety of factors including: migration and 




proliferation of keratinocytes. This process occurs within 48-72 hours of wounding and is 
illustrated in Figure 5.40 
 
 
Wound edge keratinocytes migrate away from the wound. Consequently, keratinocyte 
migration initiates recruitment of basal and wound edge level keratinocytes and epithelial 
stem cells. These constituents nucleate the proliferation process.40 Proliferation is triggered 
by loss of physical tension and cell adhesion to desmosomes and hemi-desmosomes, which 
is governed by CD-44, a cell-to-cell adhesion molecule. Membrane associated kinases 
increased permeability to calcium. This facilitates reorganization of the cytoskeleton and 
increases constituent migration.41  
 As migration progresses cells are released from their original sites. This process is 
mediated through the triggering of collagenase and elastase, resulting in the creation of 
new adhesion structures. Once these structures are created, migration is terminated.42 




Keratinocytes secrete proteins to rebuild the basement membrane, which marks the 
beginning of the re-epithelization process.43 This process is initiated by nitric oxide that is 
synthesized by macrophages as well as various growth factors (endothelial growth factor, 
keratinocyte growth factor, IGF-1, and nerve growth factors).44 
Following re-epithelization, neovascularization begins. Initiation of this process is 
governed by vascular endothelial growth factor (VEFGF), PDGF, basic fibroblast growth 
factor (bFGF), and serine protease thrombin.43-45 In concert, these growth factors activate 
endothelial cells of the residual vessels. Culminating in the secretion of proteolytic 
enzymes that dissolve the basal lamina. This dissolving process facilitates migration and 
proliferation of endothelial cells toward angiogenic stimulus. The impact of angiogenesis 
allows for the reformation of vessel lumens, arteries, and venules. Angiogenesis matures 
through recruitment of pericytes and smooth muscle cells, which restore functionality to 
the wounded area.45 
Once granulation tissue forms, the provisional wound matrix formed during 
hemostasis is replaced. Granulation tissue is composed of fibroblasts, granulocytes, 
macrophages, blood vessels, and collagen bundles. Together, these constituents restore 
structure and function to the wounded skin. Fibroblasts contained within granulation tissue 
begin to proliferate. This serves a critical role in tissue formation. These fibroblasts migrate 
from the dermis in response to growth factors such as: PDGF, TGF-β, and bFGF, 




originate from fibrocytes and bone marrow derived mesenchymal progenitor cells.47 They 
migrate to regions of skin injury and contribute cytokines, chemokines, as well as 
previously discussed growth factors; further, they serve as antigen presenting cells to 
enhance angiogenesis.48 
Overall, fibroblasts migrate into the provisional cell matrix and produce matrix 
metalloproteinase (MMPs) to degrade the provisional matrix. Once the provisional matrix 
is degraded, collagen and extracellular matrix components are deposited. These include: 
proteoglycans, hyaluronic acid, glycosaminoglycans, and fibronectin. Constituents are 
formed from granular tissue and provide a scaffold for cell adhesion, growth, migration, 
and differentiation.49-52 
1.4. The Maturation Phase 
Maturation initiates at the terminal point of granulation tissue development, this 
phase of wound healing is illustrated in Figure 6.40 As mentioned before, mechanical 
tension and cytokines spur fibroblast differentiation into myofibroblasts. These cells 




express α-smooth muscle actin (SMA), which acts to contract the wound.53 Complete 
wound healing is characterized by myofibroblast apoptosis, which allows for the 
replacement of collagen III with collagen I, in the extracellular matrix. Consequently, the 
extracellular matrix exhibits higher tensile strength, a decrease in new blood vessels, and 
diminished blood flow. Environmentally, this creates an avascular and acellular condtion.54 
In cases of serious injury, hair follicles and sweat glands cannot be fully recovered, 
commonly known as scarring; wherein, newly healed skin achieves ~80% of its original 
tensile strength.55 
1.5. Chronic Wounds: 
 The aforementioned wound healing processes are exhibited when a wound 
undergoes normal wound healing. In chronic wounds, various growth factor equilibriums 
can be unbalanced. Consequently, wound fluid fails to stimulate DNA synthesis. DNA 
synthesis failure reduces the level of PDGF, bFGF, EGF, and TGF-β.56 Conversely, growth 




effectively rendering them inactive. Further, presence of wound proteinases inhibits growth 
factor activity.57 Figure 758 shows a representation of this cascade.  
Development of disruptions in acute wounds facilitates chronic inflammation. 
Physiologically, chronic inflammation is characterized by an increased concentration of 
inflammatory cytokines, leading to a higher population of neutrophils, macrophages, and 
mast cells. These cells, in turn, secrete proteases and reactive oxygen species. Over time, 
these constituents are chronically elevated culminating with off-target destruction of 
essential proteins for healing. Prolonged destruction of these proteins leads to the 
development of a chronic, non-healing wound.59  




Wound healing phase disruptions are characterized by complications with 
chemotaxis, hemostasis, neovascularization, and reepithelization.60 These processes are 
mediated through a variety of in-vivo signaling pathways, including the endocrine, 
autocrine, paracrine, and intracrine pathways. Cellular mediation is carried out by 
cytokines utilizing nitric oxide and other cellular elements.61 Process completion is 
characterized by cellular recruitment of macrophages and neutrophils, as well as collagen 
network development. As the wound heals, it develops a particular pH gradient, where each 
phase can be identified. Overall, irregularities in developmental milestones do not allow 
for proper wound closure, which increases the likelihood of scarring.61 
1.6. Chemical and Physical Biomarkers used in Current Biosensors:  
In order to accurately and precisely monitor wound healing progression, flexible 
biosensors are utilized to quantify specific biomarkers (e.g. glucose, IL-6, lactate, pH and 
oxygen). These biomarkers are integral to discerning wound progression and status. Such 
biomarkers provide clinicians continuous data when coupled to a point of care system. 
Wound site values for glucose, lactate, pH, oxygen, interleukin-6, temperature, and blood 
pressure elucidate healing progression and inflammation status.62 Implicated biomarkers, 
along with what they indicate, normal physiological ranges, illness values, and main 





In cases of skin injury of the lower extremities, patients with diabetes mellitus are at an 
increased risk of amputation, as blood circulation and oxygenation of tissue is 
comprimised.71 In wound healing, deficiencies in growth factor production due to high 
levels of glucose inhibits growth factor production, angiogenesis, macrophage function, 
collagen deposition, keratinocyte and fibroblast aggregation at the wound site, and scar 
strength.71 Current methods in measuring glucose levels depend on electrochemical 




generate direct current. Over time, sensing can be tuned to select for enzymatic and non-
enzymatic glucose. Sensing enzymatic glucose utilizes immobilized glucose-oxidase on 
the surface of the electrode surface, degrading glucose into gluconic acid, illustrated in 
Figure 8.72  
 
Interleukin-6 is a pro-inflammatory cytokine in the inflammatory response of 
wound healing.73 Sustained, high levels of IL-6 degrade the extracellular matrix, impede 
cell migration, and prolong the inflammatory wound healing response.74 In-vivo levels of 
IL-6 range from 0-2.4 pg/mL and is absent in tissue.75 Uncharacteristic levels of IL-6 in 
blood manifest above 2.4 pg/mL and 1.27 ± 1.7 pg/μg in the wound bed. These elevated 








Lactate is produced because of oxygen deficiency during anaerobic activity.62 
Normal lactate levels range from 0.5-1.5 mM in blood; however, sustained levels above 
1.5 mM indicates hyperlactatemia.66 In healthy tissue, lactate levels are between 1-3 mM, 
fibroblast function is inhibited at concentrations above 7 mM at the wound site.76 Further 
indications of more serious conditions, occurring outside of normal blood lactate 
concentrations, that impair the wound healing process include: lactic acidosis, lactic sepsis, 
or tissue hypoxia.66 Current sensing modalities utilize chronoamperometry. 
pH is critical in determining physiological status. In chronic wounds, pH fluctuates 
between 7.15 and 8.90 in the wound bed. While undergoing tissue repair, wound bed pH 
decreases to a more acidic state of 4-7. Effectively, the acidity increases fibroblast activity, 
decreases irregular collagen formation, inhibits bacterial viability, and impairs 
metalloproteinase enzyme degradation rates.77 Conversely, a more basic pH individuates 
atypical healing, with further indications of pathogenic infection, alkalosis, or a chronic 
would.78  
 Oxygen concentration is determined by hemoglobin concentration and partial 
pressure of dissolved oxygen in blood.79 In homeostatic conditions, 97% percent of oxygen 
is transported through the bloodstream by hemoglobin, while 3% is dissolved in the 
blood.69 This results in a range of 50 to 130 μM of oxygen.80 In systemic arterial blood, the 
partial pressure of dissolved oxygen typically ranges between 95- 100 mmHg and 0 to 10 




levels in wound exudates to a range of 5 to 20 mmHg.81 Uncharacteristic levels of oxygen 
can indicate carbon monoxide poisoning, mass cell apoptosis, pH fluctuations, and 
facilitate over expression of pro-inflammatory cytokines like (IL-6, IL-1β, and TNF-α).81, 
69  
1.7 Current Bandages/Adhesives 
Current bandages and adhesives function by imparting pressure over the wounded 
surface, to facilitate clotting. Their effects are largely mechanical in nature, depending on 
location and placement on the patient. Recently, consumer bandages now contain antibiotic 
species, most commonly: neomycin sulfate, polymyxin B sulfate, and bacitracin zinc.  
Neomycin sulfate, as depicted in Figure 9, is an aminoglycoside antibiotic, 
characterized by the presence of two or more amino sugars coupled by glyosidic bonds. It 
is typically used in topical preparation; however, there are approved oral administration 
methods, the first use occurred in 1952 after approval.6 Once ingested, neomycin is not 




absorbed in the gastrointestinal tract. Through regulation of intestinal tract bacteria, 
ammonia levels are mediated. It is efficacious against streptomycin-resistant bacteria.6 
Microbes with antibacterial resistance are leading causes for infection in wounds, thus 
leading to the development of chronic wounds. These infections interfere with the normal 
wound healing processes, as the immune response is prolonged, thereby delaying the 
proliferative and remodeling phases of wound healing.82-84 Its efficacy stems from 
inhibition of protein translation in mRNA through binding with the 30S subunit of the 
ribosome.85 Further, it exhibits high binding affinity for phospholipid components of cell 
membranes, specifically phosphatidylinositol 4,5-bisphophate.86 In DNA binding, 
aminoglycosides, have high affinity for duplex RNA.7 
Polymyxin B sulfate, discovered in 1947 and shown in Figure 10, is primarily used 
for Gram-negative resistant infections, which include Escherichia coli, Pseudomonas 
aeruginosa, Neisseria gonorrhea, Chlamydia trachomatis, and Yesinia pestis.87 Their 




application in wound care is for their ability to bind to cell membranes and induce increased 
permeability, leading to increased water uptake and cell death. Chemically, it is a cationic 
peptide with basic properties with functionality akin to surfactants. Mechanistically, 
polymyxins bind to negatively charged sites in the lipopolysaccharide layer in bacterial 
outer membranes, leading to increased permeability.8 Following successful binding, 
conformational changes induce fatty acid dissolution in hydrophobic regions of the 
cytoplasmic membrane, leading to diminished membrane integrity. After fatty acid 
dissolution, cellular molecules leak out, inhibiting cellular respiration, with further 
polymyxin binding to endotoxins, leading to deativation.88 
Bacitracin zinc, as illustrated in Figure 11, is a cyclical peptide with the capacity to 
disrupt Gram-positive bacteria through cell wall interference and disruption of 
peptidoglycan synthesis. This is achieved through interaction with the dephosphorylation 




of C55-isoprenyl pyrophosphate and bactoprenol pyrophosphate. These species are both 
lipids with critical cell function. Their functionality is defined as membrane carrier 
molecules with critical significance in peptidoglycan synthesis.89 
1.8 Zeolite (QuikClot) 
Zeolite, as illustrated in Figure 12, is of particular interest in wound healing 
applications due to its cation exchange and molecular sieve characteristics. Zeolite is a 
crystalline solid composed of aluminum, silicone, and oxygen.12 In pig wound models, 
formulations of nitric oxide-zeolite particles, in ointment form, caused a 2.5-log reduction 
of viable bacterial colonies (104 CFU/gram of tissue), compared to controlled wound and 
treated wound, after six days of treatment. Further, treated wounds healed significantly 
faster than control wounds (36% vs 26% per day, p = .03).90 
Specifically, in wound healing, topically applied zeolite-based materials aid in the 
construction of scaffolds for tissue engineering. In this application, zeolite mimics the 
mineral rich component of the natural bone substrate. These composites promote 




proliferation of human fibroblasts and mesenchymal stem cells (MSCs) as well directed 
differentiation of MSCs towards osteoblasts.91 
Although zeolite material composites feature hard characteristics, zeolite has the 
capacity for application in soft-tissue-engineering, specifically in vascular and skin tissue 
systems, because of its molecular sieve characteristics. 3-D scaffolds consisting of 
polyurethane were embedded with fluorinated zeolite Y crystals. Subsequently, these 
scaffolds had a significant impact on the proliferative and penetrative capacities of human 
coronary artery smooth muscle cells.13,92 This is because of zeolite acts as a reservoir for 
oxygen, enhancing oxygen delivery to the cells.92 Increased availability of oxygen 
promotes synthesis of growth factors which facilitates cellular proliferation.93  
1.9 Polyethylene Glycol (PEG) Based Wound Sealants   
Wound sealants are used to promote reconnection and sealing of tissue after 
wounding or surgical procedures.94-95 Current challenges associated with wound closure 
include elasticity and adhesion. As an example, cyanoacrylates exhibit desirable stiffness 
and adhesion; however, is cyto-toxic, and is not elastic.96 PEG, illustrated in Figure 13, 
materials are now being utilized for  




wound sealants, as they are nontoxic and inert.97 In in-vitro studies, utilizing L929 cells 
(mouse line) PEG hydrogels treated cells exhibited long spindled shapes, with lamellipodia 
and fiopodia. These visual characteristics were evidence against cytotoxicity, as the cells 
were not presenting lysed characteristics (rounded shape).98 Quantitative viability 
assessments yielded 81% viability for test samples utilizing PEG hydrogels. When 
compared to high density polyethylene for negative control, 10% dimethyl sulfoxide for 
positive control, and culture medium for blank, of 99%, 28%, and 100% respectively. Table 











1.10 Hyaluronic Acid Based Hydrogels: 
Hyaluronic acid (HA), illustrated in Figure 14, is a type of polysaccharide of the 
glycosaminoglycan class, it consists of two sugar base units: glucuronic acid and N-acetyl-
glucosamine.99 In biological systems, HA is found in synovial fluid, surrounding joints and 
cartilage, as well as eye and dermal tissue. Recent studies have implicated HA as treatment 
agent for accelerating wound healing, increasing cellular proliferation, and improving skin 
graft quality. These studies are tabulated in Table 3.100  





1.11 Chondroitin Sulfate (CS): 
 While commercial bandages and topical ointments have been heavily utilized and 
are the state-of-the-art, there has been a growing interest in using natural/biopolymers for 
applications in biomaterial development, along with tissue engineering and wound healing. 




ubiquitous in the extracellular matrix (ECM). GAG functionality is derived from their 
negatively charged polysaccharides. These anion sites present efficacious characteristics 
such as: ECM and bind effector molecule hydration capability.9,107-108 CS, specifically, 
consists of a repeating network of sulfated disaccharide, which contain N-
acetylgalactosamine. CS chains are classified by type: A, C, D, E, H and K.10 They are 
named CS A (C-4-S), C (C-6-S), D (C-2,6-S), E (C-4,6-S), K (C-3,4-S) and H (IdoAa1–
3GalNAc(4S,6S)), illustrated in Figure 15. C-4-S and C-6-S are the most ubiquitous.  
Figure 15. Chemical Structure Denoting Sulfonation Differences in Chondroitin Sulfate 




During the proliferative phase of wound healing, CS is released. This phenomenon 
implicates CS as an integral constituent in the wound healing process. In wound healing, 
injection of glycylhistidyl-lysine-Cu2+, a wound healing activator, into rat wound models, 
results in accumulation of CS, resulting in stimulation of wound tissue production, as 
shown in Figure 16 and demonstrated in 2000 by Simeon.11  
 
In nasal mucosa, at the 4-day endpoint, CS hydrogels have been found to accelerate 
wound healing.109 Of particular significance is understanding CS’s efficacy in regulation 
Figure 16. Injection of GHK-Cu Increases Accumulation of GAG in the Wound 
Chamber, as Measured by Total Uronic Acid  
Content Reprinted with permission from “Expression of glycosaminoglycans and small 
proteoglycans in wounds: modulation by the tripeptide-copper complex glycl-L-histidyl-





of cellular adhesion, proliferation, cell cycle, and performance in in-vitro 2-D and 3-D 
wound closures, and contraction rate.  
 In fibroblast adhesion, CS impact was demonstrated through culture of fibroblasts 
in the presence of chondroitinase ABC (an enzyme that breaks down CS). After culture, 
degradation of exogenous CS reduced the number of adherent cells significantly. This 
suggests that CS is necessary for cell adhesion. Conversely, fibroblasts cultured in medium 
supplemented with exogenous CS exhibited increased cell adhesion.110 This phenomenon 
is demonstrated graphically in Figure 17.110  
 
CS regulated fibroblast proliferation has been documented and assessed through 



















Figure 17. Regulation of fibroblast adhesion by CS. Degradation of Cs by the addition of 
Chondroitinase ABC to the culture medium for 8hrs lead to a decrease in the number of adherent 




degradation of CS was the treatment, the number of proliferating cells was significantly 
reduced. This result suggests that CS is integral to successful cell proliferation. In 
fibroblasts, cultured in the presence of CS, cell proliferation increased, illustrating the 
importance of CS to cellular proliferation.11,109-110 
 In order to elucidate the effect of extraneous CS in the 2-D wound healing model, 
the effect of the absence of CS was first analyzed. In this model, the effect of chondroitinase 
ABC on wound closure was assessed, where the measurement parameter was wound 
closure. After investigation, wound distance, in the presence of chondroitinase ABC, 
decreased 75.3% in 18hrs after wounding, compared to 92.6% reduction in the 2-D wound 
model, without extraneous CS or chondroitinase ABC. In the presence of extraneous CS 
(1000 ng/ml), wound closure was significantly accelerated (p < .05). In the 3-D wound 
healing model, fibroblast gel contraction was observed within 24 hours after cell seeding. 




inhibited cell-gel contraction, 72 hours after gelling, yielding only 6% contraction, depicted 
in Figure 18.110  
 Cell adhesion is integral to successful wound healing.111 The affect that CS had on 
fibroblast adhesion may be attributed to integrin medial cell adhesion. This results in 
localization of focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase. 
Localization of FAK is concentrated at focal adhesion points, as well as tyrosine 
phosphorylation of FAK.112-112 α4β1 integrin has been reported a binding site for CS.
114 In 
order to enhance FAK phosphorylation, CS is needed for α4β1 integrin-mediated cell 
adhesion.115 Further, the ability for CS to bind to fibroblast growth factor-2 (FGF-2) may 
assist FGF-2 induced cell proliferation.116-117 The FGF consists of 22 derivative growth 
Figure 18. The association of CS in wound contraction. (A) Cell-gel had more than 50% contraction 
after 72hrs. (B) Addition of C-4-S had no significant effect. (C) Addition of C-6-S led to almost no 
contraction. (D) Comparison in the difference of contraction rates  
Reprinted with permission from “Specific interactions between human fibroblasts and particular 
chondroitin sulfate molecules for wound healing” by XH Zou, 2009, Acta biomaterialia, 5(5), 1588-





factors, with the capacity to stimulate proliferation of gingival fibroblasts. In rabbit models, 
topical application of FGF-2 resulted in accelerated healing of gingival ulcers.118-119 
 In the 2-D wound healing model, the function of extraneous CS promotes cellular 
migration and dispersion. CS proteoglycan facilitates cellular dispersion and migration 
through activation of FAK and inhibition of RhoA activity.115 Facilitation of cellular 
dispersion and migration, by FAK, down-regulates RhoA activity. RhoA is a member of 
the GTPase family, wherein its activation forms focal adhesions and stress fibers, 
illustrating how high levels of RhoA inhibits cellular migration.120 Figure 19121 illustrates 
Figure 19. Signaling pathways of FAK and Src, controlling actin cytoskeletal rearrangement, and 
FAs. Integrin β1 can be activated by reelin and induces recruitment and stimulation of FAK and 
Src, which control cell migration and adhesion via regulation of the actin cytoskeleton and FA 
complex. 
Reprinted with permission from “Abnormal cell properties and down-regulated FAK-Src complex 
signaling in B lymphoblasts of Autistic subjects” by Hongen Wei, 2011American J. of Pathology, 








the interaction between the signaling pathway of FAK and Src kinase controlling 
cytoskeleton rearrangement and ultimately impacting cellular migration and adhesion.   
Regarding the function of CS in the 3-D wound healing model, 3-D matrices 
composed of type I collagen have been utilized historically. 3-D models are more 
congruent with natural physiological processes associated with wound healing, than 2-D 
models.122-123 In the 3-D model, CS was able to efficiently mediate the contraction process 
of collagen by human fibroblasts through inhibition. Together, this suggests that CS, as a 
treatment, is able to abate contractile behavior of fibroblasts. The overall impact, although 
specific mechanisms have not been described in the literature, is correction of 
uncharacteristic fibroblast activation, with therapeutic applications.110 
1.12 Engineering Biosensor Devices Utilizing Graphene-Based Materials 
 In the past, different synthetic methods yielding efficacious structural and material 
properties were utilized for the development of biosensing application. This is due to 
graphene being a semi-metal with ultra-high charge mobility, large surface area, and the 
capability for surface functionalization.17 Many different methods exist to engineer the 
biomolecular receptor for biosensing. In the biomedical field, pristine graphene is referred 
to as an oxide-free graphene, presenting with π-π stacking, non-covalent interactions, and 
high electrostatic force. Further, it allows for an infinite sensing surface at the molecular 
level. Thus, graphene has a high probability of presenting active sites for charge-




capability as well as the supporting desired functionalization to the target biomolecule of 
interest. Figure 2017 illustrates differing interactions of graphene-based systems. As an 
example, the areas of pure graphene as shown in the figure can provide a charged space to 
interact any molecules of interest or metal ions, with further interactions at the vacancy 
defect. Functionalized graphene areas are able to directly detect biomolecules by intrinsic 
oxide components due its synthetic process where a great deal of epoxide, hydroxyl, and 
carboxyl groups are formed and accumulate on the edges and surface sites. Additionally, 
functionalized graphene allows for binding of heteroatoms, nanoparticles (NPS), quantum 
dots (QDs), DNA enzymes, proteins, antibodies, and antigens.124-126 
 In biomedical use cases, nanostructures based of graphene have been recently 
reported to have highly selective and sensitive characteristics as biosensors, for biomarkers 
associated with wound healing, as tabulated in Table 4.17 







1.12.1 Engineering Biomolecule Based Biosensors using Pristine Graphene  
 With graphene-based biosensors, graphene improves the sensitivity, limit of 
detection (LOD), and the overall performance of the biosensor. This is done by enhancing 
the charge or electron transfer between the graphene and biomolecule of interest. As an 
example, for a label-free and portable aptasensor scheme, pristine graphene is utilized for 
the electrode in a field effect transistor.136 The biosensor detects Pb2+ ions in children’s 
blood. There are varied components in blood, as it is composed of Na+, K+, Mg2+, and Ca2+, 
at levels lower than 0.1 M/L. This limit, is approximately one thousandth of the safety limit 
(100 µg/L) for Pb2+ in blood.17 
 A novel, paper-based biosensor, utilizing the efficacious electrochemical 
properties of graphene, was developed for human papillomavirus (HPV).137 The sensing 
Table 4: Current graphene-based biosensors and their biomolecular targets 





GFET Graphene DNA 10 pM 127 
GpO FET GpO/Cu or AgNPS Glucose 1 µM 128 
RGO FET Urease/PEI/RGO Urea 1 µM 129 
GLSPR Ni/graphene 3-NT 0.13 pg/mL 130 
SPR RGO Rabbit IgG 0.3125 
µg/L 
131 
SPR Graphene-MoS2 ssDNA - 132 
ECHEM Go-ssDNA/Au VEGF 0.05 ng/mL 133 
ECHEM Anti-human D-dimer 
antibody/lipid film/ 
graphene nanosheets 
D-dimer 1 µM 134 
Electron 
transfer 
MoS2/GO Glucose in 
human serum 




electrode was modified using a labeled peptide and printed utilizing the inkjet printing 
method. The surface chemistry involved using a negatively charged amino acid on the 
graphene electrode, by way of electrostatic attraction. The target amino acid was a synthetic 
14 base oligonucleotide with a sequence corresponding to HPV type 16 DNA. The 
electrochemical response to the label was measured and was able to identify primary stages 
of cervical cancer.  
 Integrated graphene microelectrodes with lipid bilayer membranes have 
resulted in efficacious findings, in both static and stirred experiments.138 Further, due to 
the structural properties of the membrane, the developed sensor was reusable, had high 
sensitivity, and the results were reproducible.  These characteristics, taken together, 
enabled direct potentiometric measurements.138 





Table 5 presents first, second, and third generation hemostatic products approves 
by the CoTCCC for battlefield use. Military and civilian mechanisms of injury have been 
traditionally different. However, given the rise of terrorist attacks utilizing improvised 
explosive devices (IED), more than 53,000 civilians and military personnel were killed or 
injured between 2011 and 2013 globally.20 Trauma originating from penetrating 
fragmentation used by explosive devices is now becoming more common in developed 




elsewhere.139 The best practices from battlefield lessons learned for hemorrhage control 
should be applied universally, regardless of casualty type or location.20   
 For nearly the last two decades of combat casualty care in Afghanistan and Iraq, 
the main mechanism of injury has been penetration, in approximately 75% of casualties. 
The majority of injuries were primarily caused by fragmentation of IEDs (74%). While 
more traditional wounds such as gunshot wounds and blunt force trauma comprise 22% 
and 4%, respectively.21 A majority of combat deaths occur before the patient reaches a 
surgical team. In the military, the leading cause of mortality is: hemorrhage (91%) derived 
from three key anatomical regions: truncal (67%), junctional (19%), and extremity 
(13%).22,23 
 The civilian sector’s primary mechanism of injury that leads to morbidity and 
mortality is blunt force trauma (79-89%) and penetrating trauma (11-22%). Of the 
immediate to early deaths, the proportion (50-60%) from either cause is constant, with 
death being the primary result of traumatic brain injury or hemorrhage. These findings have 
been constant over many decades.24-25,139-140 In austere settings, traumatic brain injury or 
trauma effecting multiple body systems is the leading cause of morbidity or mortality, 
where victims fall from height.141-145 
1.13 Effectiveness and Evolution of Hemostatic Agents/Dressings 
 Historical use of hemostatic agents and dressings for mitigating bleeding, by the 




1996 TCCC Guidelines did not have US Food and Drug Administration (FDA)-approved 
hemostatic agents useable for battlefield care.147 Ensuing research into hemostatic agents 
endeavored to develop an efficacious product to mitigate major bleeding within minutes of 
wounding, that was both safe for the patient and the medic; easy to use for stakeholders, 
easy to transport and rugged, has a long shelf life, and cheap.149 During the 2003 TCCC 
guideline revision, several products were efficacious in controlling bleeding in animal 
models.150-154 
 The primary agents that were selected for battlefield casualties were the chitosan-
based bandage HemCon (HemCon Medical Technologies, Portland, OR) and the zeolite-
based powder QuikClot (Z-Medica, Wallingford, CT). Efficacy was equal in both products 
for controlling severe bleeding, based on pre-clinical studies; however, no product was 
more advantageous at the time.20 Of note, military surgical teams reported first, second, 
and third-degree burns were observed in surrounding tissue after QuikClot application. 
These burns were explained by the exothermic reaction that occurs when blood makes 
contact with the zeolite granules after application in soft tissue wounds.155 Because of these 
adverse effects, the Committee on Tactical Combat Casualty Care (CoTCCC) designated 
HemCon bandages as the preferred initial hemostatic agent.26  
 The CoTCCC undertook a literature review on hemostatic dressings for application 
in tactical medicine guideline revisions.20 This review consisted of input from combat-




with QuikClot and HemCon. Additionally, a review of the literature was conducted to 
elucidate new information utilizing animal models for efficacy. Overall, however, the 
CoTCCC did not select an obvious winner for efficacy based off of laboratory studies or 
case reports in practice.20 In 2006, the TCCC guidelines were revised, resulting in both 
HemCon bandages and QuikClot granules being recommended to be carried on the 
battlefield. However, QuikClot was designated as the secondary agent of choice to 
HemCon.149,156 
 Following the 2006 TCCC revision, published in the Prehospital Trauma Life 
Support Manual, new hemostatic agents/dressings were evaluated by the United States 
Army Institute of Surgical Research and the Navy Medical Research Center found that two 
new materials, QuikClot Combat Gauze (Z-Medica) and WoundStat (TraumaCure, 
Bethesda, MD) were more effective on a consistent basis, than the previously reported 
agents (QuikClot and HemCon)157,158. As a result, the CoTCCC voted to recommend 
QuikClot Combat Gauze as the primary treatment for critical hemorrhage that is not suited 
for placement of tourniquets, with WoundStat designated as the secondary agent.29 The 
reasoning used for this prioritization was based on the experience of medics and corpsmen 
preferring gauze type hemostatic agents, as powdered or granulated agents were less 
effective in wounds where the bleeding vessel is located in a narrow wound tract or in 
windy battlefield conditions.147 However, due to subsequent animal testing, WoundStat, a 
granular material, was removed from the TCCC guidelines as a secondary to QuikClot 




 Between 2008 and 2014, no formal reviews were conducted for new hemostatic 
agents/dressings. New, consistent data derived from animal models for severe hemorrhage 
show chitosan-based hemostatic gauze dressings for battlefield applications are as effective 
as QuikClot Combat Gauze. A total of eight studies reported equivalence and efficacy of 
chitosan-based dressings with QuikClot Combat Gauze in preclinical models of extremity 
arterial hemorrhage.29, 160-167 Additional studies reported successful outcomes utilizing 
updated chitosan-based dressings (Celox Gauze, MedTrade Products Ltd, Crew, UK) in 
the civilian sector, based on hospital case reports168-170 and prehospital battlefield case 
reports.171-172 Additionally, no safety concerns or complications have been reported in these 
cases, across the years of chitosan-based hemostatic dressing use (HemCon and Celox) in 
applications for the military173-174 or in civilian sectors.175 Utilizing the evidence based 
literature review, the CoTCCC chose to add ChitoGauze Pro and Celox Gauze (HemCon 
Medical Technologies, Portland OR) into the TCCC Guidelines as well as QuikClot 
Combat Gauze.29 Since 2008, QuikClot Combat Gauze has remained as the primary 
hemostatic dressing due to its utility and effectiveness.20  
 In 2015, a new FDA approved hemostatic product called XStat (RevMedx, 
Wilsonville, OR) was incorporated into the CoTCCC guidelines.176 Effectiveness was 
based on product utility and preclinical animal wound models.163,177-178 The need for the 
XStat exists in deep-tract or narrow-entrance wounds, aiding in hemorrhage control. Its 
efficacy is defined through its use of a syringe delivered, expandable, nonabsorbable, 




compressible wounds, i.e. wounds were tourniquets are not applicable. Once the sponges 
make contact with blood, they expand – filling the wound cavity, providing pressure as 
well as a physical barrier in the wound to aid clot formation. Overall, the device is for 
temporary use, up to 4 hours until surgical care can be rendered. XStat cannot be used in 
in the abdomen, thorax, the retroperitoneal space, sacral space, tissues above the clavicle, 
or above the inguinal ligament. XStat was designed for use in the battlefield or civilian 
tactical medical environments, and austere environments for low and high velocity gunshot 
wounds.20  
 The first XStat study163 tested efficacy utilizing porcine models with subclavian 
and artery and vein bleeding, developed through a 4.5 cm wound. This model was utilized 
as subclavian wounds are more difficult to compress when compared to junctional areas 
that allow for efficacious pressure distribution during hemostatic gauze application. In the 
XStat study group, there were 8 animals as well as 8 in the control group utilizing QuikClot 
Combat Gauze. XStat was applied within 4 minutes of wounding. In the control group, one 
animal was treated with Kerlix gauze and another was treated with QuikClot Combat 
Cause. For this group, the dressings were applied with 3 minutes of direct pressure, 
according to the directions supplied by the manufacturer. During the 60-minute time point 
(the golden hour) survival was 100% (8/8) in the XStat group and 37.5% (3/8) in the 




A study undertaken by the Naval Medical Research Unit, San Antonio juxtaposed 
QuikClot Combat Gauze with XStat, utilizing a large animal model with subclavian 
bleeding. The study reported XStat could be applied in less time than QuikClot Combat 
Gauze (31 seconds verses 65 seconds), resulting in less blood loss during time of 
application. In the XStat study, survivability of the subclavian vascular injury was 
100%. This wound pattern is critical as it is highly lethal in trauma patients.177 
2. Experimental 
2.1 Materials  
Chondroitin sulfate (CS) sodium salt was purchased from Santa Cruz Biotechnology. 
Methacrylic anhydride (MAA, 94%, contains 2000 ppm toponal A as inhibitor), 
polyethylene glycol diacrylate (PEGDA, Mn = 700 Da), 3-(trimethoxy silyl) propyl 
methacrylate (TMSPM, 98%), and (3-aminopropyl) triethoxysilane (APTES, 99%) were 
purchased from Sigma Aldrich. Sodium hydroxide pellets (97%, ACS reagent) was 
purchased from Acros Organics. Lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate 
(LAP, >98%) was purchased from TCI chemicals. 2-propanol (ACS plus), tetrahydrofuran 
(THF, anhydrous) and acetone (Certified ACS) were purchased from Thermo Fisher. 200 
proof ethanol, anhydrous, was purchased from Decon labs. pH buffers 4-10 were purchased 
from Inorganic Ventures. All chemicals were used without further purification. Purified DI 
water (18.2 MΩ resistance) used for synthesis and hydrogel formulation was obtained 
using Milli-Q IQ 7000 DI water system. 6 well, nunclon delta plates were purchased from 




eagle medium, 10% fetal bovine serum, and 1% penicillin-streptomycin (PenStrep) were 
purchased from Thermofisher Scientific. Trypsin-EDTA (.25%) were purchased from 
Thermofisher Scientific.  Human keratinocyte (HaCaT) cells were graciously provided by 
Dr. Jeffery Travers, of Wright State Physicians.  
2.2 Chondroitin sulfate-methacrylate (CS-MA) synthesis  
Wang et al.179 synthetic procedure was modified for the synthesis of CS-MA. An 
example procedure is as follows: 3 g chondroitin sulfate sodium salt was added to a 3-
necked RBF, equipped with nitrogen inlet and an additional funnel, and dissolved in 150 
mL DI water at room temperature. 57 g of methacrylic anhydride (MAA, 0.370 mol) was 
rapidly added dropwise through the addition funnel to the solution with vigorous stirring. 
Upon complete addition of MAA, 5 N NaOH solution was added to the mixture until the 
pH = 8. NaOH was added as necessary to maintain basic pH for 2 h at room temperature. 
After stirring for 2 h, the RBF was sealed and stored in the fridge for 12 h without stirring. 
The CS-MA was precipitated in excess IPA (3:1 IPA:reaction volume) and stirred for 1 h. 
The solid was allowed to settle for at least 1 h without agitation and then the excess IPA 
was decanted. The residual CS-MA gel-like solid that remained was dissolved in the least 
amount of DI water possible and precipitated in IPA. The polymer fibers that formed were 
stirred in IPA for 1 h followed by a subsequent stirring in 200 proof ethanol for 12 h to 





2.3 Chondroitin sulfate-methacrylate polyethylene glycol (CS-MA-PEG) hydrogel 
synthesis  
Hydrogels were synthesized using the procedure as follows: 1 g CS-MA was 
dissolved in 5 mL DI water. 1 g of PEGDA was added to the solution and stirred. 12.5 mg 
of LAP (0.042 mmol) was added to the solution and dissolved. The hydrogel solution was 
slowly pipetted into a Teflon mold with 4 wells (1 cm x 1 cm x 0.5 cm) which was placed 
on a level metal plate. The solution was exposed to 366 nm UV light (Model UVL-56, 
Blak-ray lamp, 115 volts, 60 Hz, 0.16 amps) for at least 30 min. The crosslinked hydrogels 
were removed and stored in DI water.  
2.4 Characterization 
Proton nuclear magnetic resonance (1H NMR) spectroscopy was performed on a Bruker 
operating at 400 mHz. 1H NMR spectra were obtained from 4.3% (w/v) 0.7 mL solutions 
in d-H2O using 64 scans. FT-IR measurements were taken using a Bruker Alpha-R module. 
Thermal analysis was conducted using a TA instruments Thermogravimetric Analyzer 
(TGA) Q500. The TGA was equipped with an autosampler and nitrogen and air purge 
inlets. Cell cycle effects were gauged utilizing a BD Accuri C6 Plus flow cytometer. The 
flow cytometer was equipped with an autosampler, and volume intake was limited to 1 mL. 




devices were conducted using a Cascade Microtech GmbH (type: MPS150-B1A) multi-
probe platform with a Keithley interactive test environment interface.  
2.5 Graphene Growth 
A tube furnace (OTF-1200x-STM, MTI Corp., CA) equipped with a scroll vacuum 
pump was used for chemical vapor deposition (CVD) of graphene.180 A 5x1 inch2 copper 
(Cu) foil was placed in the furnace and was heated up to 1000 oC at a pressure of 125 mTorr 
maintained with a fixed flow of hydrogen. The hydrogen-only reduction step continued for 
30 min at 1000°C, which was followed with a flow of methane at a pressure of 1.25 Torr 
for 30 min at 1000°C. The furnace was cooled down to room temperature while keeping 
the flow of methane and hydrogen. After completion of the growth, graphene was observed 
on both sides of the Cu foil. The Cu foil was cut into 0.5 cm x 0.5 cm pieces for transferring 
to silicon substrates. 
2.6 GFET Chip Preparation  
A silicon wafer having 285 nm thermal oxide was diced into ~ 1.8 cm x 1.4 cm 
(width x length) pieces, which are used as substrates. After cleaning a silicon substrate 
using acetone and isopropanol, source/drain electrodes for the GFET were made using 
photo-lithography, e-beam evaporation and lift-off. The process involved sequential use 
of double-layer photo-resist (LOR10A/AZ 5214), ~ min of UV exposure, AZ 300 MIF 




evaporation of 1 nm Ti and 40 nm Au, tape lift-off, 1 min acetone spray and finally 
soaking in Microposit Remover 1165 for 5 min at 95 oC. 
2.7 Graphene Transfer 
Transfer of graphene onto a silicon substrate was done using PMMA as the support 
layer. By protecting one side of the Cu foil containing graphene with aluminum foil, 
graphene from the unprotected side was removed using reaction ion etching (RIE) for 5 
min at 50 W RF power and using 200 mTorr O2. Graphene on the other side of the Cu 
foil was then cleaned using acetone and IPA and then coated with a single drop (~ 50 µl) 
of 950K PMMA (purchased from MicroChem; diluted to 1% w/v in anisole). The solvent 
was removed by heating to 70 °C for ~30 min. The PMMA-coated graphene on Cu-foil 
was then exposed to ~ 254 nm UV (Novascan PSD-UV) for 30 min in ambient air. (This 
step reduces PMMA residue from the graphene surface at the end of the transfer 
process.181) PMMA-coated graphene/Cu piece was then placed in Fe(NO3)3 solution (5% 
w/v in deionized water) for ~ 6 hrs to etch Cu; the process leaves graphene supported by 
PMMA on Fe(NO3)3 solution. The Fe(NO3)3 solution was later replaced with DI water; a 
few drops of isopropanol were added to water such that IPA:water ratio is 1:6. (Use of 
IPA in water helps the adhesion of PMMA-coated graphene to silicon surface.182) 
Subsequently, PMMA-coated graphene was lifted from the IPA/water mixture and placed 
onto a silicon substrate containing pre-patterned Ti/Au electrodes. The substrate was 




graphene from the IPA/water mixture. The substrate was annealed at 70 °C in air for 20 
mins to adhere PMMA-coated graphene to the substrate. The sample was stored at room 
temperature PMMA for 3-4 hrs to dry the residual solvents. An ~ 50 µl of acetone was 
dropped on PMMA-coated silicon substrate and later dried off. The acetone drop/dry 
process was repeated three times to uniformly adhere graphene to the silicon surface. 
PMMA was then removed by placing the silicon substrates vertically in acetone at ~45oC 
for 30 mins.  
2.8 GFET Definition 
Graphene was then patterned within the channel (length ~ 10 µm, width ~ 16 µm) area 
of GFET using photolithography and O2 plasma etching. 
2.9 GFET Surface Modification and Coating with Hydrogel 
 Graphene FETs were rinsed with acetone and IPA to remove any debris on the chip 
surface. The chips were submerged in an APTES or TMSPM solution (5 v:v% in THF) for 
10 min. The chips were immediately rinsed with acetone and placed on a level metal plate. 
5 µL of the CS-MA-PEG solution was added to the center of the chip and cured for at least 
10 min (as described in 2.3). The hydrogel devices were used for testing immediately. 
2.10 GFET Device Testing 
 The pH sensitivity of the GFET device was tested with and without the hydrogel 




point probe measurement was set up (ground: 0 V, 0.105 A compliance). An initial voltage 
sweep (10 µA, 10 V compliance, 10 data points) was collected three times to get a 
resistance measurement (from I-V curve) for the device. 0.5-1 µL of pH buffer 4-10 (added 
sequentially) was to the center of the device and resistance measurements were collected. 
The voltage sweeps were conducted every 30 sec for at least 2 min or until the resistance 
measurements stabilized. In between each buffer, DI water was used to wash the device 
and the water was removed and the device was air dried for at least 30 sec (only for devices 
without hydrogel coating, resistance measurements were collected prior to adding more 
buffer).   
2.11 Human Keratinocyte (HaCaT) Cell Culture 
HaCaTs were cultured following a previously reported method.11 HaCaTs were seeded 
(4x104 cell/mL) in Nunc (ThermoFisher Scientific) cell-culture treated dishes. They were 
allowed to culture for 6 days, until 80-90% confluent. Media was changed every other day. 
After visual inspection, plates were placed into the culture hood, with laminar flow and 
UV light sterilization. Culture media was aspirated and fresh media was added into each 
well. Culture was conducted with media levels at 5 mL per well plate, with media being 
changed every other day. After confluency was achieved, determined through optical 
microscopy, CS-MA-PEG hydrogels were added to probe cell cycle effects. Effects were 





2.12 Flow Cytometry of Treated & Untreated HaCaT Cells 
Cells were prepared following a protocol provided by BD. In summary: cells were 
trypsinized for 10 minutes. After addition of trypsin, cells were relocated to the incubator 
for 10 minutes. Following this, trypsin was inactivated through addition of an equal volume 
of cell growth media. After inactivation, cells were pelleted through centrifugation for 2 
minutes at 1500 RPM at 4°C. the supernatant was aspirated and the pellet was washed with 
1 mL of phosphate buffered saline (PBS) and pelleted again. After pelleting, the 
supernatant was aspirated and 200 µl PBS 1 mL of ice cold 100% ethanol was added, with 
gentle vortexing. the sample was stored in a -20°C freezer overnight. the cells were spun 
at 1500 RPM for 2 minutes in a centrifuge, and resuspended in in 500 µl of PBS. 
3. Results & Discussion 
3.1 Chondroitin Sulfate-Methacrylate (CS-MA) Synthesis  
 A series of CS-MA hydrogels were synthesized using slightly modified procedures 

















We obtained similar results as described, with increasing amounts of excess MAA added 
to the reaction, an increasing degree of substation could be obtained. This was confirmed 
by FT-IR, shown in Figure 22. The FT-IR illustrates an increasing peak intensity around 
1713 cm-1, corresponding to the ester carbonyl bond stretching of the methacrylate. The 1H 
NMR data also showed the methacrylate was successfully substituted onto the CS 
backbone (Figure 23b). The neat CS 1H NMR spectrum is provided for comparison (Figure 
23a). The 1H NMR was used to calculate the degree of substation by averaging the 
integration of the protons corresponding to the alkene of the methacrylate group. We used 
the methyl group of the CS amide as a reference (~1.91 ppm). The reference was 




“validated” (to compare to other samples and the neat CS) if the peak around 3.26 ppm 
integrated to around 1. This peak corresponds to the amide proton and remained constant 
regardless of the degree of substitution. The maximum degree of substation using this 
method is 300%, because CS has 3 hydroxyl groups that could be substituted. The highest 
degree of substation we were able to obtain was ~67% (less than 1 hydroxyl group 
substituted per repeat unit). This is likely due to the competing side reactions that could 
occur during the synthesis. The hydroxyl functional groups on the CS compete against 
water as a nucleophile. A large excess of MAA was necessary because the anhydride would 
likely be hydrolyzed in the NaOH (in water) reaction solution. In addition, steric hindrance 










3.2 Chondroitin sulfate-methacrylate-polyethylene glycol (CS-MA-PEG) hydrogel 
synthesis 
 The CS-MA-PEG hydrogels were synthesized via radical polymerization using a 
UV-active photo-initiator, lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate (LAP). 
LAP was chosen as the photo-initiator because of its good water solubility and 
a. 
b. 




cytocompatibility compared to Irgacure 2959, which is another common photo-initiator.  












The PEGDA used has a nominal Mn = 700 Da, which is roughly 13 PEO repeat units. We 
attempted to make a hydrogel with a lower molecular weight PEGDA crosslinker, 
however, due to poor water solubility, the resulting hydrogel was opaque and brittle. The 
700 Da PEG based hydrogels had good mechanic properties (qualitatively) and produced 




transparent hydrogels. A systematic study was conducted to optimize the hydrogel 
formulation, where cure time and monomer ratio (CS-MA:PEGDA w:w) were varied. The 
most robust hydrogel was formulated using a 1:1 CS-MA:PEGDA w:w and cured for at 
least 30 min. When the cure time was less than 30 min, incomplete curing occurred, which 
was indicated by cracking and embrittlement once the hydrogel was submerged in H2O. 
Additionally, when the monomer ratio was altered, the resulting hydrogels exhibited 
undesired properties. When a higher weight ratio of CS-MA in relation to PEGDA, the 
resulting hydrogel had very little compressibility and fractured easily when hydrated (when 
compressed in hand). A similar result occurred when there was a larger amount of PEGDA 
used. When the weight ratios were equal, the resulting hydrogel was ductile and more 
compressible in the hydrated and non-hydrated state in comparison.  
3.3 Graphene Field Effect Transistor (GFET) device and pH testing 
 Our objective with this experiment was to illustrate that our hydrogels could be 
combined with GFETs to monitor the pH of a wound. The concept was if the hydrogel 
could absorb the wound fluid (and facilitate wound healing), the pH sensitivity of graphene 
could be utilized to continuously monitor the pH of the wound in conjunction with the 
hydrogel coating.  
The GFETs each contained 10 devices, however, for the device testing, only 1 was 









There have been several studies reported on graphene-based devices for pH sensing. For 
comparison, we tested the pH sensitivity of our graphene devices with and without a water 











Figure 25. a) GFET device without hydrogel coating 




Figure 26. Blank GFET devices average change in resistance as a function of pH  





The charts illustrate that there is an overall increase in resistance with increasing pH. This 
trend in opposite of what was reported by Lei et al183 with their simple graphene-based 
sensor. However, this trend was consistent with all of the devices that we tested, so the 
response was validated. The water wash was used to remove any residual buffer that we 
believed could have remained on the surface of the graphene after each test. It was assumed 
that if residual buffer evaporated on the graphene surface, the resistance would increase 
until enough salt collected on the graphene surface, destroying the device. From the figures, 
it is clear that the resistance increased exponentially in both experiments. However, the 
resistance increased sooner without the water wash between buffers, as expected.  
 The devices were coated with the CS-MA-PEG hydrogel and Figure 25b illustrates 
a typical device. A silane surface modification was necessary in order to improve the 
interfacial adhesion between the hydrophilic hydrogel and the hydrophobic graphene 
surface. Two silane coatings were used, 3-(trimethoxy silyl) propyl methacrylate 
(TMSPM) and (3-aminopropyl)triethoxysilane (APTES). The devices were coated by 
submerging the chip in a dilute solution of the silane. Initially, APTES was used to modify 
the surface with amine groups, which would improve the hydrophilicity of the substrate. 
However, the electrostatic interaction between the hydrogel and the amine groups were 
significant enough to stop the hydrogel from peeling once the hydrogel became hydrated 




hypothesis was the methacrylate surface would contribute to the crosslinking network 
during the curing phase, and the physical crosslinking of the hydrogel onto the chip surface 
would provide a much better adhesion even when the hydrogel was hydrated.  
The results of the device coated with TMSPM and the hydrogel are shown in Figure 
27. The hydrogel has significantly improved adhesion and remained on the chip after buffer 
was added. It should be noted that the pH buffer was not removed in between each new 
addition of buffer because the hydrogel did an effective job of absorbing it. After an initial 
equilibration period, the device had a clear decrease in resistance with an increase in buffer 
between pH 4-7. This decrease in pH is different than what was observed with the bare 
GFET devices, which supported our original hypothesis that the graphene sensor could be 
used to monitor the change in pH. The results suggest that the graphene could potentially 
be sensing changes in the CS morphology as a function of pH. The results illustrate a 
parabolic type of response over the entire pH range, which will require further 
investigation. However, it is suspected that the pKa of the CS-MA-PEG hydrogel is around 
pH 7-8, which would account for a change in morphology, resulting in an increase in device 
resistance. The resistance only decreases once the hydrogel is given time to equilibrate at 








3.4 Thermogravimetric Analysis (TGA) of CS-MA-PEG hydrogels  
TGA was utilized as a robust way to get qualitative information about the 
morphology of the hydrogel at between pH 4-10. Our hypothesis was, if there was a change 
in morphology around pH 7-8 (as suggested by the resistance measurements), then that 
would be reflected by the bound/unbound water (weight loss) of the hydrogel. It is expected 
that as the polymer undergoes a morphology change, for example, a coiled state vs 
uncoiled, the amount of tightly bound water would change. Tightly bound water in this 
experiment was measured as the weight loss between 100-150 °C. The hydrogels were 
hydrated for at least 3 days and patted dry to remove any excess water. The results of this 





















pH vs Resistance Response of CS-MA-PEG 
Hydrogels Coupled with GFET





The CS-MA starting material and the hydrogel soaked in DI water were given for 
comparisons, black and blue line, respectively. It should be noted that the average total 
water content for all of the hydrogels was ~72%, which includes both bound and unbound 
water. As hypothesized, the hydrogel that was soaked in pH 8 buffer had an unbound water 
content of 67% and a bound water content of 5%. This is in stark contrast to every other 
experiment where the unbound water ranged from 51-61 wt.% and bound water ranged 
from 12-21 wt.%. This provided some evidence that there could be some morphology 
change that contributed to the observed increase in resistance around pH 8.  
3.5 Flow cytometry of treated and untreated HaCaT cells 
Flow cytometry was used to elucidate cell cycle effects such as cell count and cell 










































Unbound/Bound Water Change as a Function of pH
Unbound Water Bound Water
Figure 28. Unbound/bound water change of CS-MA-PEG hydrogels as a 




for 6 days, and their confluence was validated through optical microscopy. After 
confluency was achieved, the cells were treated with .5cm x .5cm x .25 cm segments of 
CS-MA-PEG hydrogels. The hydrogels functioned as a scaffold for cell growth. Because 
of the inherent porosity and high water content of the hydrogel, the cells were able to 
permeate through the hydrogel. The cells were allowed to culture for 5 days, and cytometry 
experiments were conducted on day 1,3, and 5 to assess the impact the hydrogel had on the 
cell growth compared to the control. The cells were passed through a laser which counted 
each disruption of its photon flow beam as cellular event. Each beam disruption caused 
two scattering events to occur: forward and side scatter: Forward scatter (FSC) is the 
transversally projected area of a cellular event, analogous to size. Whereas side scatter is 
the axial projected area of a cellular event. Our hypothesis was that the treated cells (cells 
exposed to the hydrogel) would present with larger characteristic sizes, when compared to 
the control, and would proliferate faster, gauged through the number of cells found in a 
microliter of cellular suspension, when compared to a control. Figure 29a and 29b 





Figure 29a illustrates the effect of the hydrogel on cell size. From day 1 to day 5, 
the cells experienced a 500% increase in size, when normalized to day 1. Figure 29b 
illustrates the effect of the hydrogel on cell count, or proliferative capacity. For day 1, there 
were 46% more treated cells than control cells. This trend continued for day 3 where there 
were 129% more treated cells, and for day 5 were there were 69% more cells. Further, this 
study also demonstrates that over a 5 day incubation period, the CS-MA-PEG hydrogel 
does not have any cytotoxic effects on keratinocytes. That assumption, coupled with the 
improved cell growth, provide strong evidence for our hydrogels potential application as 











































Cell Count vs Time (Days)
Control Treated
Figure 29 a-b. Flow Cytometry Results of Hydrogel’s Cell 






In this research an attempt was made to examine the effects of a CS-MA-PEG hydrogel 
on keratinocyte growth. Additional investigations of hydrogels as a potential coating on 
graphene-based bio-sensors for continuous wound fluid pH monitoring were made. 
Further, this research successfully synthesized the CS-MA precursor reported in literature 
and established a protocol to reproduce formulations of CS-MA-PEG hydrogels with good 
mechanical and optical properties; since there are no ASTM or ISO specifications. 
 It was shown that the hydrogel-based device  could distinguish changes in pH.  The 
sensing kinetics and parameters of the combined hydrogel and graphene sensor are found 
to be parabolic. Therefore, there is a need to investigate these kinetic phenomena in more 
detail. A robust experiment using TGA was utilized to assess the morphological changes 
at various pH levels to elucidate what could be causing the specific parabolic responses. 
But, this data could only be used to speculate and vaguely support the hypothesis. Further 
structural imaging techniques could be utilized to confirm the hydrogel morphology at 
various pHs.  
In terms of accelerating wound healing, this research demonstrated facilitated 
keratinocyte growth cycles. The synthesized CS-MA-PEG hydrogel, after five days of 
treatment imparted a five-fold increase in size to keratinocytes, when normalized to a day 
1 control. Further, the hydrogels impacted keratinocyte proliferative capacity by increasing 




on day 5. These trends illustrate how keratinocytes, when they are cultured in the presence 
of the hydrogel, deposit extracellular constituents, such as collagen type 1 and collagen 
type 7, faster which will contribute to accelerated wound closure and stronger scar tissue 
development. Further, through the acceleration of proliferation between day 1 and day 3, 
the material has shown its utility in the crucial stages of wound healing. 
Further examination into the genomic response of the material in a variety of cellular 
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